Adaptive Biotechnologies Corp (ADPT)vsDanaher Corporation (DHR)
ADPT
Adaptive Biotechnologies Corp
$16.90
-6.53%
HEALTHCARE · Cap: $2.82B
DHR
Danaher Corporation
$184.30
-0.38%
HEALTHCARE · Cap: $117.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 8288% more annual revenue ($24.78B vs $295.41M). DHR leads profitability with a 14.9% profit margin vs -16.8%. DHR earns a higher WallStSmart Score of 58/100 (C).
ADPT
Avoid30
out of 100
Grade: F
DHR
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.3%
Fair Value
$31.45
Current Price
$16.90
$14.55 discount
Margin of Safety
-60.8%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.1% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Areas to Watch
Trading at 12.4x book value
0.0% earnings growth
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 35.1% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Return on Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while DHR is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.15 — expect wider price swings.
ADPT is growing revenue faster at 35.1% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (58/100 vs 30/100). ADPT offers better value entry with a 50.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?